Invivyd (IVVD) Receivables - Net (2024 - 2025)
Invivyd (IVVD) reported Receivables - Net of $13.9 million for Q4 2025, up 27.63% on a YoY basis from $10.9 million in Q4 2024, and up 41.28% quarter-over-quarter from $9.9 million in Q3 2025.
Invivyd (IVVD) Receivables - Net (2024 - 2025) Analysis & Trends
Invivyd has reported Receivables - Net for 2 years, with the latest figure at $13.9 million in Q4 2025.
- For the quarter ending Q4 2025, Receivables - Net rose 27.63% year-over-year to $13.9 million; the trailing twelve-month figure through Dec 2025 stood at $13.9 million (up 27.63% YoY), and the FY2025 full-year result was $13.9 million, up 27.63% from the prior year.
- Receivables - Net for Q4 2025 stood at $13.9 million, up from $9.9 million in the prior quarter.
- The five-year high for Receivables - Net was $13.9 million in Q4 2025, with the low at $2.9 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Invivyd | 168.41 Mn | -58.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 13.92 Mn |
| Dec 31, 2025 | 13.92 Mn |
| Sep 30, 2025 | 9.85 Mn |
| Sep 30, 2025 | 9.85 Mn |
| Jun 30, 2025 | 8.70 Mn |
| Jun 30, 2025 | 8.70 Mn |
| Mar 31, 2025 | 8.56 Mn |
| Mar 31, 2025 | 8.56 Mn |
| Dec 31, 2024 | 10.91 Mn |
| Dec 31, 2024 | 10.91 Mn |
| Sep 30, 2024 | 8.20 Mn |
| Sep 30, 2024 | 8.20 Mn |
| Jun 30, 2024 | 2.90 Mn |
| Jun 30, 2024 | 2.90 Mn |